Crispr Therapeutics Stock Been: A Roller-Coaster Year Unpacked
CRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Tax harvesting to lower capital gains automates selling decisions to reduce taxes while maintaining portfolio goals.
25,625 articlesCRISPR Therapeutics stock has zigzagged all year, driven by pipeline milestones, regulatory updates, and funding need...
Polestar is barred from selling new cars in the United States under a new connected-vehicle rule, a move analysts say...
In 2026, two very different healthcare players—Abbott Laboratories and Glaukos—offer contrasting paths to potential g...
TSMC delivers a record quarterly print as AI-driven demand powers growth. Margin expands and 2026 guidance rises, sig...
Ford faces a turning point as it expands EV capabilities while navigating a volatile market. Here are three scenarios...
Solana posted the largest ETF inflow in months on February 25, signaling renewed institutional interest. Yet on-chain...
Oil prices jump again, fueling fears of broader economic stress as supply constraints and demand resilience push benc...
Remitly (RELY) is evolving beyond simple transfers. This in-depth analysis walks through expected 2025 earnings drive...
With the CLARITY Act stalled in the Senate, XRP traders await a potential reset. A clearance could alter liquidity an...
Solana is trading near $97 as traders weigh a potential move above $100 this month. Analysts point to ETF demand and ...
Rivian sits at a pivotal crossroads. This in-depth look weighs cash, partnerships, and a road map for growth to answe...
AI-driven analysis explores XRP's possible path to higher prices if Ripple secures a Fed master account. The piece ou...